Piramal Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Cash & Equivalents	-	3,889	3,714	1,956	2,281	3,847
Short-Term Investments	-	-	-	1	7.1	31.2
Trading Asset Securities	-	195.6	1,447	4,271	504	-
Cash & Short-Term Investments	4,085	4,085	5,160	6,228	2,792	3,878
Cash Growth	-18.55%	-20.84%	-17.14%	123.06%	-28.00%	-
Accounts Receivable	-	23,757	21,348	18,144	18,086	16,081
Other Receivables	-	453.7	171.3	35.6	141.9	447
Receivables	-	24,211	21,519	18,179	18,228	16,528
Inventory	-	23,127	21,759	16,814	13,888	12,320
Prepaid Expenses	-	791.8	640.2	765.7	695.5	626.6
Restricted Cash	-	1,125	1,112	1,021	913.5	122.3
Other Current Assets	-	4,630	4,454	5,347	4,155	3,012
Total Current Assets	-	57,970	54,645	48,355	40,672	36,487
Property, Plant & Equipment	-	36,267	36,417	44,415	37,157	31,663
Long-Term Investments	-	2,711	2,403	2,119	2,168	1,227
Goodwill	-	11,482	11,226	11,075	10,305	8,565
Other Intangible Assets	-	43,354	43,415	33,382	33,053	27,094
Long-Term Accounts Receivable	-	-	-	18.6	750.6	581.8
Long-Term Deferred Tax Assets	-	3,931	3,865	3,493	2,973	2,441
Other Long-Term Assets	-	1,061	1,149	2,369	892	939.7
Total Assets	-	156,776	153,118	145,226	127,970	108,998
Accounts Payable	-	15,338	15,384	11,927	10,264	9,179
Accrued Expenses	-	2,991	2,448	2,642	2,141	1,943
Short-Term Debt	-	9,953	11,714	13,023	6,588	3,605
Current Portion of Long-Term Debt	-	5,109	9,037	8,189	7,424	2,105
Current Portion of Leases	-	370.4	333.1	303.9	184.4	214.9
Current Income Taxes Payable	-	96.1	403	35.4	716.6	394.2
Current Unearned Revenue	-	45	19.6	859	452.7	770.3
Other Current Liabilities	-	3,760	4,355	1,451	2,564	6,691
Total Current Liabilities	-	37,663	43,693	38,431	30,333	24,903
Long-Term Debt	-	32,141	24,838	33,835	26,221	23,392
Long-Term Leases	-	991.6	1,180	1,019	862	934.1
Long-Term Unearned Revenue	-	295.1	238	335.6	460.3	1,427
Long-Term Deferred Tax Liabilities	-	2,484	2,292	2,193	1,920	2,225
Other Long-Term Liabilities	-	1,462	1,442	1,471	1,082	0.8
Total Liabilities	-	75,521	74,004	77,491	61,004	52,948
Common Stock	-	13,244	13,230	11,933	11,859	9,946
Additional Paid-In Capital	-	47,372	47,249	38,187	37,252	32,495
Retained Earnings	-	10,493	9,707	9,564	11,589	8,326
Comprehensive Income & Other	-	10,146	8,928	8,050	6,267	5,284
Shareholders' Equity	81,255	81,255	79,114	67,735	66,966	56,050
Total Liabilities & Equity	-	156,776	153,118	145,226	127,970	108,998
Total Debt	48,565	48,565	47,102	56,371	41,279	30,251
Net Cash (Debt)	-44,480	-44,480	-41,941	-50,143	-38,487	-26,373
Net Cash Per Share	-33.46	-33.43	-32.68	-42.13	-32.65	-42.02
Filing Date Shares Outstanding	1,318	1,324	1,323	1,193	1,186	994.6
Total Common Shares Outstanding	1,318	1,324	1,323	1,193	1,186	994.6
Working Capital	-	20,307	10,952	9,924	10,339	11,584
Book Value Per Share	61.35	61.35	59.80	56.76	56.47	56.35
Tangible Book Value	26,419	26,419	24,474	23,278	23,608	20,391
Tangible Book Value Per Share	19.95	19.95	18.50	19.51	19.91	20.50
Land	-	1,792	1,729	1,339	1,300	1,284
Buildings	-	20,380	18,949	15,260	11,996	10,208
Machinery	-	47,560	41,626	36,473	30,662	26,853
Construction In Progress	-	4,891	5,657	8,529	6,732	3,995

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.